Product
Siponimod
Name
MAYZENT
INN Name
siponimod
FDA Approved
Yes
3 clinical trials
1 organization
1 indication
1 document
Indication
Multiple SclerosisClinical trial
Pregnancy Outcomes in Women Exposed to Diroximel FumarateStatus: Recruiting, Estimated PCD: 2031-01-17
Clinical trial
Managed Access Program (MAP) to Provide Access to Siponimod Treatment for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With no Satisfactory Alternative TreatmentStatus:
Clinical trial
Exploring the Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Patients With Advancing Forms of Relapsing Multiple Sclerosis: A 6-month Open Label, Multi- Center Phase IIIb StudyStatus: Completed, Estimated PCD: 2022-07-06
Document
DailyMed Label: MAYZENTOrganization
Novartis Pharmaceuticals Corporation